| scholarly article | Q13442814 |
| P50 | author | David Drewry | Q42811145 |
| Hassan Al-Ali | Q56000876 | ||
| Matt C. Danzi | Q87467924 | ||
| Vance P. Lemmon | Q37374728 | ||
| Krister Wennerberg | Q31058683 | ||
| P2093 | author name string | Jae K Lee | |
| John L Bixby | |||
| Do-Hun Lee | |||
| Prson Gautam | |||
| Houssam Nassif | |||
| Bill Zuercher | |||
| P2860 | cites work | Advances in the management of spinal cord injury. | Q37722134 |
| Polypharmacology - foe or friend? | Q38126927 | ||
| High content screening of cortical neurons identifies novel regulators of axon growth | Q41327476 | ||
| Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation. | Q41465954 | ||
| Kinase/phosphatase overexpression reveals pathways regulating hippocampal neuron morphology. | Q42526841 | ||
| Navigating the kinome | Q43525185 | ||
| Structure-based optimization of novel azepane derivatives as PKB inhibitors | Q44784861 | ||
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. | Q46227082 | ||
| What's wrong with drug screening today | Q46338526 | ||
| Controllability of complex networks. | Q51569838 | ||
| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. | Q51781980 | ||
| PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration | Q75447896 | ||
| Rational combinations of siRNAs targeting Plk1 with breast cancer drugs | Q79976833 | ||
| Targeting the BET family for the treatment of leukemia | Q87841494 | ||
| Spinal cord regeneration | Q87850881 | ||
| Targeting the cancer kinome through polypharmacology | Q33893019 | ||
| KLF family members regulate intrinsic axon regeneration ability. | Q33899036 | ||
| The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar | Q34190151 | ||
| Cortical PKC inhibition promotes axonal regeneration of the corticospinal tract and forelimb functional recovery after cervical dorsal spinal hemisection in adult rats | Q34321826 | ||
| Mammalian target of rapamycin's distinct roles and effectiveness in promoting compensatory axonal sprouting in the injured CNS. | Q34491707 | ||
| Chemical interrogation of the neuronal kinome using a primary cell-based screening assay | Q34616753 | ||
| Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains | Q35533503 | ||
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity | Q35591349 | ||
| Rho kinase, a promising drug target for neurological disorders | Q36111908 | ||
| Phosphorylation of paxillin by p38MAPK is involved in the neurite extension of PC-12 cells | Q36321832 | ||
| Axonal regeneration in adult CNS neurons--signaling molecules and pathways | Q36395710 | ||
| Combinatorial treatments for promoting axon regeneration in the CNS: strategies for overcoming inhibitory signals and activating neurons' intrinsic growth state | Q36827341 | ||
| Target deconvolution strategies in drug discovery | Q36961595 | ||
| Chemical genetic discovery of targets and anti-targets for cancer polypharmacology | Q36988960 | ||
| Axonal growth therapeutics: regeneration or sprouting or plasticity? | Q37131897 | ||
| S6 kinase inhibits intrinsic axon regeneration capacity via AMP kinase in Caenorhabditis elegans | Q37479461 | ||
| Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen | Q24300657 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Statistical methods for analysis of high-throughput RNA interference screens | Q24644919 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) | Q24799034 | ||
| Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers | Q26995259 | ||
| Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy | Q27682798 | ||
| Drug discovery: playing dirty | Q28276831 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation | Q28577018 | ||
| P90 Ribosomal s6 kinase 2 negatively regulates axon growth in motoneurons | Q28585535 | ||
| Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
| How were new medicines discovered? | Q29616641 | ||
| The specificities of protein kinase inhibitors: an update | Q30014834 | ||
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies | Q30436867 | ||
| Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS) | Q30486521 | ||
| Kinome-wide activity modeling from diverse public high-quality data sets | Q30582708 | ||
| Minimum redundancy feature selection from microarray gene expression data | Q30988046 | ||
| P433 | issue | 8 | |
| P921 | main subject | polypharmacology | Q21823227 |
| P304 | page(s) | 1939-1951 | |
| P577 | publication date | 2015-06-24 | |
| P1433 | published in | ACS Chemical Biology | Q165583 |
| P1476 | title | Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth | |
| P478 | volume | 10 |
| Q48140499 | Can Astrocytes Be a Target for Precision Medicine? |
| Q39612715 | Casein kinase signaling in axon regeneration |
| Q38716951 | Exploiting kinase polypharmacology for nerve regeneration. |
| Q39037865 | High content analysis in amyotrophic lateral sclerosis |
| Q47733373 | High content analysis of phagocytic activity and cell morphology with PuntoMorph. |
| Q48183777 | High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell derived neurons. |
| Q56889371 | Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data |
| Q38716618 | In vitro models of axon regeneration |
| Q91554531 | Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites |
| Q38881147 | Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics |
| Q92402554 | Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D |
| Q38668995 | Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery. |
| Q38647605 | Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes |
| Q36125734 | Phenotypic Screening of Small-Molecule Inhibitors: Implications for Therapeutic Discovery and Drug Target Development in Traumatic Brain Injury |
| Q35729506 | Phenotypic assays to identify agents that induce reactive gliosis: a counter-screen to prioritize compounds for preclinical animal studies |
| Q38904862 | Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. |
| Q38646648 | Progress towards a public chemogenomic set for protein kinases and a call for contributions |
| Q36774566 | RegenBase: a knowledge base of spinal cord injury biology for translational research |
| Q57821582 | Scaffold Ranking and Positional Scanning Identify Novel Neurite Outgrowth Promoters with Nanomolar Potency |
| Q47726286 | The mTOR Substrate S6 Kinase 1 (S6K1) Is a Negative Regulator of Axon Regeneration and a Potential Drug Target for Central Nervous System Injury |
| Q89651597 | Turning liabilities into opportunities: Off-target based drug repurposing in cancer |
Search more.